The Role of Angiopoietins in Cardiovascular Outcomes of Kidney Transplant Recipients: An Ancillary Study from the FAVORIT
Gendy N, Brown L, Staunton M, Garg K, Hernandez Garcilazo N, Qian L, Yamamoto Y, Ugwuowo U, Obeid W, Al-Qusairi L, Bostom A, Mansour S. The Role of Angiopoietins in Cardiovascular Outcomes of Kidney Transplant Recipients: An Ancillary Study from the FAVORIT. American Journal Of Nephrology 2024, 55: 597-606. PMID: 38735283, PMCID: PMC11444892, DOI: 10.1159/000538878.Peer-Reviewed Original ResearchKidney transplant recipientsRisk of cardiovascular diseaseGraft failureCardiovascular disease developmentAngpt-2Cardiovascular diseaseIncreased risk of future CVDAncillary studiesClinical variablesCare of kidney transplant recipientsIncreased riskRisk of future CVDUrine albumin-to-creatinine ratioDonor kidney transplant recipientsAlbumin-to-creatinine ratioIncreased risk of cardiovascular diseaseFuture cardiovascular diseaseImproves prediction of cardiovascular diseaseTransplant-related variablesAssociated with outcomeParticipants' median ageMitigate CVD riskMedian ageTransplant recipientsMedian time